Tremelimumab (anti-CTLA-4)

製品コード：A2021         Batch: A202102

印刷

Tremelimumab (Ticilimumab, CP-675,206) is a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of activated T lymphocytes.

製品説明

CAS No. 745013-59-6
Formulation PBS Buffer, PH 7.4
Isotype Human IgG2
Source HEK293 Cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Purity 99.68%
Protein concentration 2.7 mg/ml
Endotoxin Level <1 EU/mg

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

In situ and dynamic screening of extracellular vesicles as predictive biomarkers in immune-checkpoint inhibitor therapies [ J Nanobiotechnology, 2025, 23(1):411] PubMed: 40457452

人間や獣医の診断であるか治療的な使用のためにでない。